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In the search for an eminently practical strategy to develop immunostimulants and vaccines 
for farmed fish, we have devised recombinant viral antigens presented as “nanopellets” 
(NPs). These are inclusion bodies of fish viral antigenic proteins produced in Escherichia 
coli. Soluble recombinant proteins are too labile to endure the in vivo environment and 
maintain full functionality, and therefore require encapsulation strategies. Yet when they 
are produced as nanostructures, they can withstand the wide range of gastrointestinal 
pH found in fish, high temperatures, and lyophilization. Moreover, these nanomaterials 
are biologically active, non-toxic to fish, cost-effective regarding production and suitable 
for oral administration. Here, we present three versions of NPs formed by antigenic 
proteins from relevant viruses affecting farmed fish: the viral nervous necrosis virus coat 
protein, infectious pancreatic necrosis virus viral protein 2, and a viral haemorrhagic 
septicemia virus G glycoprotein fragment. We demonstrate that the nanoparticles are 
taken up in vitro by zebrafish ZFL cells and in vivo by intubating zebrafish as a proof of 
concept for oral delivery. Encouragingly, analysis of gene expression suggests these NPs 
evoke an antiviral innate immune response in ZFL cells and in rainbow trout head kidney 
macrophages. They are therefore a promising platform for immunostimulants and may 
be candidates for vaccines should protection be demonstrated.
Keywords: viral antigens, protein nanoparticles, fish, bacterial inclusion bodies, oral vaccines
inTrODUcTiOn
Viral diseases are a major concern in the aquaculture industry. Vaccine strategies need to optimize 
efficacy, while taking into account production and administration costs, environmental risks, and 
compliance with legislation. The traditional approach is based on the use of inactivated or attenuated 
viral vaccines, which are commercially available for certain viral diseases that cause high mortal-
ity (1). Such vaccines induce a strong immune response when combined with oil adjuvants (2). 
However, not all fish viruses are readily culturable in cells, for example, lymphocystis disease virus 
(3), and the process is expensive, with administration via injection, or immersion for juveniles. 
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Another consideration is the risk of possible reversion to viru-
lence and environmental spread. New strategies are thus being 
sought. Among them, recombinant DNA vaccines have achieved 
promising results against certain viruses (4, 5) but raise safety 
issues regarding genetically modified organisms (6). In fact, only 
one DNA vaccine, Clynav® (Elanco) against salmonid alphavirus 
subtype 3, has been recently licensed in Europe. Like other DNA 
vaccines, it is administered by labor intensive intramuscular 
injection. Injection is costly and difficult to perform on juveniles, 
as well as causing stress and injury to fish. An alternative vaccine 
approach is the use of recombinant protein viral antigens. These 
subunit vaccines can be produced in bulk, but have been variable 
in efficacy (1). One promising format, virus-like particles (VLPs), 
uses self-assembling viral capsid proteins produced in yeast, bac-
teria, or cell culture, drawing on advances in human and animal 
vaccinology (7, 8). The main advantage of subunit vaccines is they 
are safe. There is no risk of DNA integration into the host, rever-
sion, or invasion. The main drawback is the stability and half-life 
of recombinant proteins in vivo. Oral delivery would be the most 
practical, least stressful delivery method; however, immunorele-
vant epitopes need to be protected against gastrointestinal pH, 
which is particularly low in carnivorous fish [see Figure 1 in Ref. 
(9)], as well as digestive enzymes within the tract. Thus different 
encapsulation techniques such as alginate and chitosan are being 
tested, aiming to protect the recombinant protein antigens from 
rapid degradation when inside the animal (10).
Here, we present a novel approach to finfish prophylactic 
design. To enhance the stability of antigenic proteins while 
maintaining functionality, we have nanostructured viral protein 
antigens as bacterial inclusion bodies (IBs). IBs are highly sta-
ble, tuneable, nanoscale protein particles which can penetrate 
cells, while retaining significant biological activity, as demon-
strated by rescue studies (11). They can be designed to bear the 
antigenic protein/epitopes of interest and provide a slow release 
of functional protein over time (12). The attractiveness of IBs as 
a fish prophylactic is manifold. Their stability at gastrointestinal 
pH (13) would allow administrating the antigen orally through 
the feed, avoiding the necessity for vaccine encapsulation and 
the cost and stress to fish associated with injection. Production 
in Escherichia coli is achieved in bulk with a simple enzymatic 
and mechanical purification procedure which minimizes costs 
(14). This straightforward process implies that the IBs carry 
over fragments of bacterial lipopolysaccharide, peptidoglycans, 
and nucleic acids as impurities, but which are known adjuvants 
and immunomodulators of fish (15). The IB vehicle, a carrier 
and viral antigen as one biomaterial, should elicit both an 
innate and adaptive immune response against the target virus 
in fish. Finally, IBs’ stability under lyophilizing conditions and 
over a range of temperatures (13) indicates their potential as 
a practical farm product with a lasting shelf life, avoiding the 
cold chain.
We have already demonstrated the potential of IBs as an 
immunostimulant for fish, by nanostructuring recombinant 
cytokines TNF-α and CCL4 and testing them in a bacterial infec-
tion model in zebrafish (13). In addition, uptake of the TNF-α 
IB by intestinal cells was demonstrated in vivo in rainbow trout 
via oral intubation (13). This paved the way for work focusing 
on producing viral antigens as IBs, to explore this approach for 
immunostimulus, and ultimately as a viral vaccination strategy.
This paper is a proof-of-concept study concerning the pro-
duction, uptake in  vitro and in  vivo and innate immunogenic 
potential of fish viral antigens configured as recombinant IBs. 
Given our final aim is their use in fish food, we have coined the 
term “nanopellets” (NPs) to refer to these novel nanostructured 
antigens. We chose three target proteins of known antigenicity 
from significant viruses affecting farmed finfish, reviewed in Ref. 
(6). They are the viral capsid protein 2 (VP2) from infectious 
pancreatic necrosis virus (IPNV) an Aquabirnavirus causing high 
mortality in young salmonids, the glycoprotein G of viral haem-
orrhagic septicemia virus (VHSV), a Novirhabdovirus which is 
a current OIE listed fish viral disease (http://www.oie.int/en/
animal-health-in-the-world/oie-listed-diseases-2018/) primarily 
affecting farmed trout and turbot, and the C coat protein of viral 
nervous necrosis virus (VNNV), a Betanodavirus affecting sea 
bass, sea bream, flounder, and sole, among many other fish (16). 
We show the NPs can be produced by cost-effective, reproducible 
methods and can be taken up in ZFL (zebrafish liver cell line) 
and in vivo by zebrafish (Danio rerio) when orally administrated. 
Moreover, we show the viral antigen NPs can evoke an immune 
response in vitro, upregulating gene markers of the innate viral 
immune response in ZFL and rainbow trout (Oncorhynchus 
mykiss) head kidney macrophage cell cultures.
MaTerials anD MeThODs
Design, Production, and characterization 
of nanostructured Viral antigenic Proteins
Viral Strains and Plasmids
For the three target viruses, sequences for the antigenic proteins 
of interest were: VNNV coat protein gene from the Iberian 
betanodavirus isolate (strain SpSs-IAusc160.03), NCBI GenBank, 
accession no: NC_024493.1 which is a reassortant RGNNV/
SJNNV strain (17); IPNV capsid protein 2 from the IPNV (strain 
Sp 31-75), Uniprot KB Q703G9 Chain (PRO_0000227873) 
position 1–442; VHSV glycoprotein G from the viral hemor-
rhagic septicemia virus (strain 07-71), Uniprot KB P27662. 
Clones were designed using the ORF and pET22b in a strategy 
removing the periplasmic location signal and including a C ter-
minal polyHistag. Clones were codon optimized for expression in 
E. coli, synthesized by GeneArt (Thermo Fisher Scientific) and 
subcloned into pET22b. Recombinant plasmids were transformed 
into E. coli BL21(DE3) (Novagen). Upon protein production (see 
Production of NPs, Purification, Quantification, and Fluorescent 
Labeling) the VHVS-G protein showed hallmarks of being toxic 
for E. coli, with slow host growth and scant protein yield post 
production (data not shown). This clone was substituted by 
VHSV-G-frg16 cloned into pRSETa, which covers the C-terminal 
half (amino acid residues 252–450) of the VHSV (07-71) G 
protein sequence (NCBI Genbank X59148) to the 3′end, with 
the Cys residues mutated to Ser to facilitate expression in E. coli. 
The sequence includes a putative integrin receptor RGD-binding 
site and two regions which induce Mx gene expression (18, 19). 
Furthermore, frg16 is able to bind specific anti-VHSV rainbow 
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trout antibodies in fish surviving VHSV infection (20). Apart 
from the viral antigen constructs, a construct with the red fluo-
rescent protein (RFP), iRFPHis cloned in pET22b (Genscript), 
was also transformed into E. coli BL21(DE3) to be used as a non-
immune-relevant control protein.
Production of NPs, Purification, Quantification, and 
Fluorescent Labeling
Production of nanostructured viral and control proteins from the 
clones transformed into E. coli followed the method described in 
Ref. (13). Briefly, E. coli was cultured in LB with ampicillin (Sigma-
Aldrich) at 100 µg/ml, and recombinant protein expression was 
induced with 1  mM IPTG (Panreac) when OD550 nm reached 
0.5–0.8. After a further 3 h growth at 37°C, IBs were isolated via a 
straightforward enzymatic and mechanical disruption of the cells 
according to Ref. (13). Finally, the nanostructured proteins were 
subject to sterility tests without antibiotic on LB-agar overnight 
and in DMEM culture medium (Gibco) at 37°C for 3 days. Pellets 
of purified NPs, named IPNV-VP2NP, VHSV-G-frg16NP, and 
VNNV-CNP, were stored at −80°C until use. Protein was quanti-
fied by western blot using an anti-His-tag antibody (Genscript 
A00186-100), and the protein concentration was calculated 
from a standard curve using recombinant protein and Quantity 
One software (Bio-Rad). Quantification was further tuned via 
spectrometry by comparing 100 µg/ml dilutions of the different 
NPs at 320  nm and using the correction factor determined to 
adjust the quantification accordingly. For experiments to visual-
ize the nanoparticles by flow cytometry or confocal microscopy, 
NPs were conjugated with Atto-488 NHS ester (Sigma-Aldrich) 
according to the manufacturer’s instructions. Labeling efficiency 
was determined on a fluorometer (Jasco FP8200). Equal volumes 
of nanoparticles at 100 µg/ml were treated with 6 M guanidinium 
chloride (Sigma-Aldrich) to denature overnight (O/N) at room 
temperature (RT) in the dark and the fluorescence intensity was 
read the next morning (see Figure S1 in Supplementary Material).
Characterization of Viral Recombinant Protein NPs
We used Field Emission Scanning Electron Microscopy (FESEM, 
Zeiss Merlin) to determine the external morphology and physical 
dimensions of the NPs. Samples were prepared by resuspending 
NPs at 100 µg/ml in distilled water, pipetting 20 µl onto silicon 
chips, and air drying O/N. Images were analyzed using Fiji open 
source image processing package (21), measuring the dimensions 
of a minimum of 120 particles for each construct. Size distribu-
tion histograms were generated using Past3 software (v3.18, 
University of Oslo).
In Vitro assays
Cell Cultures
Zebrafish ZFL cells (CRL-2643, ATCC) were cultured according 
to Ref. (22) at 28°C and 5% CO2 in DMEM + GlutaMAX (Gibco), 
10% heat-inactivated fetal bovine serum (FBS) (Gibco), 0.01 mg/
ml insulin (Sigma-Aldrich), 50  ng/ml epidermal growth factor 
(Sigma-Aldrich), 2% (v/v) antibiotic/antimycotic (Gibco), and 
0.5% (v/v) trout serum which had been filtered (0.20-µm filter 
Corning) and heat inactivated for 30 min at 45°C, before storing 
at −20°C. Rainbow trout head kidney macrophages (RT-HKM) 
were isolated from O. mykiss (109 ± 18 g body weight) following 
previously described procedures (23). Primary adherent cultures 
were established in DMEM + GlutaMAX, 10% heat-inactivated 
FBS and 100 µg/ml Primocin (Invitrogen) at 16°C and 5% CO2. 
Experiments for NP uptake and gene expression were performed 
on day 5 when the macrophages were fully differentiated.
Uptake of Nanostructured Viral Antigens by ZFL
To test cellular uptake, fluorescently labeled NPs were added to 
ZFL cultures at 70% confluence after 2–3 h incubation in minimal 
media (0–0.5% FBS) at the doses and times indicated below. For 
dose–response assays, VNNV-CNP and IPNV-VP2NP were added 
at 5, 10, and 20 µg/ml; and VHSV-G-frg16NP at 1, 5, 10, and 20 µg/
ml. Cultures were then incubated O/N (12–14 h). In time course 
experiments, NPs were added at 10  µg/ml for VNNV-CNP and 
IPNV-VP2NP; and at 5 µg/ml for VHSV-G-frg16NP and cultures 
were simultaneously incubated for 6–48 h before harvesting. Both 
dose–response and time course experiments were performed in 
duplicate. Post treatment, cells were washed in PBS and incubated 
at 28°C with 1 mg/ml Trypsin (Gibco) for 15 min. This strong 
trypsinization step aimed to remove NPs attached to the cell 
surface (24). Then, two volumes of complete medium were added, 
and cells were retrieved by centrifugation at 300 × g for 5 min. 
Pellets were resuspended in PBS for flow cytometry (FACSCalibur 
BD), and 10,000 events were counted. Data were analyzed using 
Flowing Software 2.5.1 (University of Turku, Finland) and plotted 
with Prism 6.01 (GraphPad). A one-way ANOVA was performed 
with Dunnett’s multiple comparisons test, comparing treatment 
and control means. To confirm the fluorescent NPs were inside 
the cells, we performed confocal microscopy (Zeiss LSM 700). 
ZFL cells were seeded on Nunclon Δ Surface individual well plates 
(Nunc). The next day cells at approximately 60% confluence were 
placed in minimal media. NPs were added 2–3 h later as follows: 
VNNV-CNP and IPNV-VP2NP at 20 µg/ml and VHSV-G-frg16NP 
at 10 µg/ml. Cells were incubated for 14 h at 28°C. Medium was 
replaced with minimal media in which the cells were stained 
with DAPI (nuclei) and Cell mask Deep Red (membrane) (Life 
Technologies). Images were analyzed using Imaris software v8.2.1 
(Bitplane).
NP Cytotoxicity Studies in ZFL
Cytotoxic and cytostatic effects of NPs on ZFL were checked 
using an MTT assay. After 2.5  h on minimal media, cultures 
were stimulated with NPs at 10, 20, and 50 µg/ml and incubated 
for 14 h at 28°C. Cells were washed in PBS and MTT substrate 
(Sigma-Aldrich) was added to 10% total volume. Controls were 
cells with no NPs, cells with no NPs but treated with 1% Triton 
(Sigma-Aldrich) before adding MTT, and cells with no NPs and 
no MTT. Cells were further incubated at 28°C for 6 h. The solu-
tion was removed, cells were solubilized in DMSO and the lysate 
read on Victor 3 (PerkinElmer) at 550 nm. The experiment was 
repeated twice. Data were normalized using Prism 6.01 (Graph 
Pad) such that the control readings were set at 100% and the 
Triton treatment readings were 0% viability, being equivalent 
to cells without MTT. A one-way ANOVA was performed with 
Dunnett’s multiple comparisons test, comparing treatment and 
control means.
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Gene Expression Analysis in ZFL and RT-HKM 
Treated With NPs
ZFL cells at 60% confluence were cultured in minimal media 
(0–0.5% FBS) for 2–3  h and then stimulated for 14  h with 
NPs at the following concentrations in triplicate: VNNV-CNP 
and IPNV-VP2NP at 10  µg/ml, VHSV-G-frg16NP at 5  µg/ml. 
Controls were poly(I:C) 25 µg/ml (Sigma-Aldrich) as a viral 
dsRNA mimic and iRFPNP at 10 µg/ml as an immunogenically 
irrelevant protein, as well as control cells with no stimulus. 
Total RNA was extracted using TriReagent (Sigma-Aldrich) 
following the manufacturer’s instructions. RNA was quantified 
using the nanodrop ND-1000 (Thermo Fisher Scientific) and 
integrity was checked on the Agilent 2100 Bioanalyzer using 
the RNA 6000 Nano Lab-Chip kit (Agilent Technologies). 
The experiment was repeated, and four complete sets of high 
quality RNA from two independent experiments were selected 
for cDNA synthesis using 1 µg of total RNA and iScript cDNA 
synthesis kit (Bio-Rad). Quantitative real-time PCR (qPCR) 
was performed at 60°C annealing temperature using iTaq 
Universal SYBR Green Supermix (Bio-Rad) with 250  nM of 
primers and 2.5 µl of cDNA previously diluted to 1:25 for the 
target and 1:500 for the reference gene, elongation factor 1 
alpha (ef1-α) (25). Primers were designed for six zebrafish gene 
markers of the innate immune response to viral infection (mx, 
viperin (vig1), gig2, irf7, stat1b, and ccl4) using NCBI Primer 
BLAST, and revised using Oligoanalyzer 3.1 (Integrated DNA 
Technologies). The primer sequences and accession numbers 
are listed in Table S1 in Supplementary Material. All the 
samples (N =  4 per treatment) were run in triplicate, and 
data were analyzed for individual replicates using the Livak 
method (26). Statistical analysis used a one-way unpaired 
t-test to compare each gene’s mean fold change in expression 
with control using Welch’s correction for unequal variances 
(Prism 6.01, GraphPad).
A further gene expression experiment was carried out in 
RT-HKM primary cultures using the two NPs made with 
antigenic proteins from virus affecting salmonids, IPNV and 
VHSV. The macrophage cultures were prepared as described 
in Section “Cell Cultures.” On day 5, cultures from three trout 
at approximately 70% confluence were placed in serum-free 
media for 2  h at 16°C. Cultures were stimulated for 15  h as 
follows: IPNV-VP2NP and VHSV-G-frg16NP at 10  µg/ml; and 
controls: poly(I:C) at 10 µg/ml and iRFPNP at 10 µg/ml, as well 
as cells with no stimulus. The experiment was repeated twice. 
Total RNA was extracted and quantified as described above for 
ZFL. From the two independent experiments, four sets of high 
quality RNA were selected for cDNA synthesis and qPCR as 
described above. The trout primer sequences were obtained 
from published papers or were designed with NCBI primer 
BLAST, selecting genes which were reported to be upregulated 
in VHSV infection of O. mykiss (27). The reference gene used 
was ef1-α (28) with cDNA diluted to 1:500. The dilution factor 
for the other genes tested was 1:50 (vig1, mx,  and ccl4) or 1:25 
(ifit5 and mda5). The primer sequences and accession numbers 
are listed in Table S1 in Supplementary Material. Data analysis 
was performed as described above.
In Vivo assays
Animals
Adult wild-type zebrafish (D. rerio) and rainbow trout (O. mykiss) 
fish were maintained at 27 ± 1 and 17 ± 1°C, respectively, in a 
12 h light/dark cycle, fed twice daily with a commercial diet at 2% 
ratio. All animal experiments were performed in accordance with 
the ethics statement at the end of the manuscript.
Uptake of NPs by Zebrafish via Oral Intubation
To test in vivo uptake of NPs, the fluorescently labeled nanopar-
ticles were intubated in zebrafish adults for the indicated times 
and doses, mimicking an oral vaccine administration route. 
Zebrafish adults (mean weight 0.9 ± 0.2 g) were acclimatized in 
tanks without feeding for 1.5 days prior to the experiment. Atto 
labeled NPs were intubated into the animals in a volume of 30 µl 
PBS using a gastight Hamilton syringe (Hamilton Company) 
with a thin silicon tube (0.30 mm inner diameter, Dow Corning) 
placed over the needle as a protective sheath to avoid injuring the 
animal. To guide oral insertion, a more rigid 10 µl filtered pipette 
tip end (NerbePlus) was cut and fixed over the tubing leaving 
the soft end exposed. Immediately prior to intubation, fish 
were anesthetized in 120–140 mg/l MS-222 (tricaine mesylate) 
(Sigma-Aldrich). Preliminary small scale runs at 3, 6, 24, and 
48  h at 20  µg and 50  µg/fish indicated maximum uptake was 
achieved by 6 h and 20 μg/fish dose was sufficient. Then runs 
were performed with groups of N = 8 fish for each NP at 20 µg/
fish in 30 µl PBS for 5 h. Controls were fish intubated with 30 µl 
PBS without NP. Post administration, fish were maintained in 
tanks until time of sacrifice using an overdose of MS-222. The 
intestine was dissected out from euthanized fish and washed 
in PBS. Next, it was incubated in 1 ml of collagenase solution: 
DMEM (Gibco) with 1% v/v antibiotic/antimycotic (Gibco) and 
collagenase Type IV (Gibco) 1.5 mg/ml at RT on a roundabout 
in the dark for 1 h. The intestine was passed through a 100-µm 
cell strainer (Falcon, Corning), washing with PBS and cells were 
retrieved by centrifugation at 400 × g for 10 min at 4°C. Cells 
were resuspended in PBS for flow cytometry (FACSCalibur 
BD), and 10,000 events were counted. Data were analyzed using 
Flowing Software 2.5.1 (University of Turku, Finland) and plot-
ted with Prism 6.01 (GraphPad). A one-way unpaired t-test with 
Welch’s correction for unequal variances was performed to test 
equivalence of means between each experimental group and 
controls.
statistical analysis
Analyses were performed with Prism 6.01 software (GraphPad), 
and Imaris 8.2.1 (Bitplane) for the confocal images and Past3 
(v3.18, University of Oslo) for data obtained from FESEM. Data 
are shown as mean ± SD. Comparisons of means for each experi-
mental group versus control were performed using a one-way 
unpaired t-test with Welch’s correction for unequal variances. 
For the in vitro uptake studies, in which we compared a series of 
conditions with the same NP, a one-way ANOVA was used, fol-
lowed by Dunnett’s multiple comparisons test for each treatment 
versus control; p < 0.05 was considered statistically significant in 
all analyses.
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resUlTs
characterization of nanostructured Viral 
antigenic Proteins
We successfully produced the three viral proteins in E. coli as 
bacterial IBs (i.e., NPs) (Figure S2 in Supplementary Material) 
with yields post purification as follows: IPNV-VP2NP 104 mg/l, 
VHSV-G-frg16NP 120 mg/l, and VNNV-CNP 50 mg/l. The NPs 
had distinct morphologies and sizes as seen in the FESEM 
images (Figure 1). IPNV-VP2NP, the largest of the NPs, is gener-
ally barrel shaped and porous; VHSV-G-frg16NP is rounder and 
smoother, while VNNV-CNP has an irregular surface with small 
spherical protrusions. We have observed similar morphologies 
in other IBs produced in E. coli in the same strain BL21(DE3) 
and in M15(pREP4) (13). The size range is shown in Figure 1 
(ii and iii) with average width and length being 607 ± 115 and 
734 ± 195 nm for IPNV-VP2NP; 488 ± 107 and 608 ± 121 nm for 
VHSV-G-frg16NP, respectively, and 422 ± 87 nm for VNNV-CNP 
mean width. The morphological features of the nanostructured 
control protein iRFPNP have already been published (14).
Uptake of Viral nPs by ZFl
All three NPs were taken up by ZFL cells. In dose–response 
experiments, uptake of VHSV-G-frg16NP was found to be par-
ticularly efficient, achieving ~100% fluorescent cells at 10 µg/ml 
O/N [Figure 2B (i)]. Hence, an additional lower dose (1 µg/ml) 
for this NP was included in subsequent experimental runs. For 
IPNV-VP2NP and VNNV-CNP, uptake increased progressively 
with dose, reaching a maximum of ~60 and 50% fluorescent 
cells, respectively [Figure 2A (i) and Figure 2C (i)]. In all cases, 
the mean fluorescence intensity (MFI) increased with dose, 
indicating susceptible cells were still able to take up more NP 
[Figures  2A–C (i) right y axis]. For time course experiments, 
a fixed dose was chosen that achieved less than the maximum 
uptake observed in the dose–response experiments. 10 µg/ml for 
IPNV-VP2NP and VNNV-CNP, and 5 µg/ml for VHSV-G-frg16NP. 
In the time course experiments, IPNV-VP2NP and VHSV-G-
frg16NP already reached the maximum percentage of fluorescent 
cells by 6  h [Figures  2A,B (ii)]. For VNNV-CNP uptake was 
slower, as the maximum percentage of fluorescent cells for the 
time points measured was at 24 h [Figure 2C (ii)]. In all cases, 
by 48 h, the percentage of fluorescent cells had started to drop 
[Figures 2A–C (ii)], possibly indicating the NPs had begun to be 
metabolized. The MFI results for the time course are consistent 
with this. Susceptible cells continued taking up NPs for the first 
24 h, then between 24 and 48 h the MFI dropped [Figures 2A–C 
(ii) right y axis].
The confocal microscopy images for IPNV-VP2NP and 
VNNV-CNP [Figures 2A,C (iii)] show that there are cells which 
have taken up a lot of NP, but others which have very few or no 
NPs. This is consistent with the cytometry results in which the 
maximum percentage of fluorescent cells which took up these 
particles O/N, at the same dose as the confocal experiments 
(20 µg/ml), were ~60 and 50%, respectively [Figures 2A,C (i)]. 
There are therefore some cells which do not up take IPNV-
VP2NP and VNNV-CNP under these conditions. By contrast, all 
cells we observed in confocal microscopy had taken up VHSV-
G-frg16NP in large quantities. This concords with the O/N 
cytometry results at the same dose (10 µg/ml), which reached 
100% fluorescent cells [Figure 2B (i)]. The digitalized z-stack 
images [Figure  2 (iii)] clearly show all three NPs have been 
internalized by the cells. For VHSV-G-frg16NP, some particles 
are also visibly embedded in the membrane and numerous NPs 
are inside the cell [Figure 2B (iii)]. The Imaris imaging software 
allows estimating the number of nanoparticles per cell. In a 
small sample, the NPs/ZFL cell were as follows (mean and SD): 
IPNV-VP2NP, 50 ± 19 NPs/cell and 67% of cells counted had NPs 
(n = 9); VNNV-CNP, 57 ± 31 NPs/cell and 65% of cells had NPs 
(n = 20); VHSV-G-frg16NP, 88 ± 45 NPs/cell and 100% of cells 
had NPs (n = 11).
Finally, the MTT assays in ZFL incubated with 10, 20, 
and 50 µg/ml of each NP for 14 h showed no significant dif-
ference in survival between control and any treatment group 
indicating that none of the NPs are cytotoxic (see Figure S3 in 
Supplementary Material). Moreover, in the intubation experi-
ments in zebrafish up to 48 h (see Uptake of NPs by Zebrafish 
via Intubation) fish showed no signs of malaise. In fact, we have 
previously injected up to 300 µg/fish of nanostructured TNF-α 
and maintained the animals for 30 days with no signs of any 
deleterious effects (13).
gene expression analysis in ZFl 
stimulated With nPs
To see whether the NPs could elicit an innate immune response 
in line with that provoked by viral infection, ZFL were stimulated 
with the three viral NPs O/N at 10 µg/ml for IPNV-VP2NP and 
VNNV-CNP and 5 µg/ml for VHSV-G-frg16NP. We used half of 
the dose of VHSV-G-frg16NP compared with the other NPs, given 
that uptake of this nanoparticle in ZFL had been greater than the 
others, even at this lower dose (see Uptake of NPs by Zebrafish via 
Oral Intubation and Figure 2B). We used poly(I:C) (25 µg/ml) as 
a viral dsRNA mimic, and iRFPNP (10 µg/ml) as a control NP made 
with an immunogenically irrelevant protein. Gene expression of 
six gene markers of the innate immune response to viral infection 
was tested by qPCR (Figure 3). For all genes tested, there was a 
remarkable similarity in the response to poly(I:C) and VNNV-
CNP, significantly different from the untreated control. For vig1 
and gig2, the upregulation was several thousand-fold for both 
treatments. For stat1b, the mean fold change (±SD) was 178 ± 32 
for poly(I:C) stimulated cells and 160 ± 41 for ZFL stimulated 
with VNNV-CNP. Mx and irf7 were upregulated between 27 ± 3- 
and 39 ± 3-fold by both treatments, while ccl4 was upregulated 
17 ± 4- and 23 ± 8-fold by poly(I:C) and VNNV-CNP, respectively. 
For the other two viral NPs, the fold change in gene expression 
was positive but much lower. IPNV-VP2NP elicited a statistically 
significant upregulation for all genes except ccl4, ranging from 
9 ± 2.4-fold for vig1 to 2 ± 0.5-fold for irf7. VHSV-G-frg16NP only 
elicited a significant upregulation for three of the genes tested: 
gig2, 7 ± 2.5-fold; stat1b, 2.5 ± 1.0-fold, and mx 1.5 ± 0.2-fold. 
iRFPNP was significantly, though slightly upregulated for two of 
the genes tested: 2 ± 0.8- and 1.7 ± 0.4-fold for irf7 and stat1b, 
respectively.
FigUre 1 | Characterization of nanostructured viral antigenic proteins. Field Emission Scanning Electron Microscopy images (i) of the three nanopellets (NPs): (a) 
IPNV-VP2NP, (B) VHSV-G-frg16NP, and (c) VNNV-CNP; with corresponding size distribution histograms (n = 120) for (ii) width (nm) and (iii) length (nm). Note there is no 
histogram (iii) for (c), as these NPs were amorphic in length.
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FigUre 2 | Uptake of viral nanopellets (NPs) by ZFL. Fluorescently labeled NPs (a) IPNV-VP2NP, (B) VHSV-G-frg16NP, and (c) VNNV-CNP were added to ZFL. Control 
(ctl) was ZFL without NPs. (i) Dose–response. Cells incubated for 12 h with NPs (a,c) at 5–20 µg/ml, and (B) at 1–20 µg/ml in duplicate. (ii) Time course. NPs 
added to cells at 10 µg/ml (a,c), and 5 µg/ml (B) in duplicate and incubated for 6–48 h. Differences between means were analyzed by a one-way ANOVA with 
Dunnett’s multiple comparisons test, treatments versus control. Significance levels *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (iii) Confocal microscopy and 
digitalized image (z-stacks) of ZFL cells after 14 h incubation with 20 µg/ml (a,c) and 10 µg/ml (B). NPs are green, cell membrane red, and nuclei blue. Control 
confocal image ZFL without NPs (D).
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FigUre 3 | Gene expression analysis in ZFL stimulated with nanopellets (NPs). Cells were incubated for 14 h as follows: unstimulated control cells (black), poly(I:C) 
25 µg/ml as a positive control (blue), IPNV-VP2NP 10 µg/ml (white), VHSV-G-frg16NP 5 µg/ml (gray), VNNV-CNP 10 μg/ml (light blue), and iRFPNP 10 µg/ml as an 
immunogenically irrelevant NP control (red). Samples are from two independent experiments. Data are mean ± SD (n = 4). Gene expression was determined by 
quantitative real-time PCR with three technical replicates. Differences between each treatment mean and control were analyzed by unpaired one-sided t-tests with 
Welch’s correction for unequal variances. Significance levels *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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gene expression analysis in rT-hKM 
stimulated With salmonid Viral nPs
As the innate immune response to VHSV-G-frg16NP had been 
weak in ZFL except for gig2, we decided to test the NP-based 
stimulus in RT-HKM primary cultures. Using macrophages 
from trout, a natural host for VHSV and IPNV would provide 
more pertinent in vitro data for the two NPs formed by salmonid 
viral antigenic proteins. We therefore incubated RT-HKM with 
IPNV-VP2NP and VHSV-G-frg16NP as well as poly(I:C) and 
iRFPNP controls all at 10 µg/ml. Genes tested included vig1, mx, 
and ifit5 which are relevant markers of VHSV infection (27), as 
well as mda5 and ccl4. For all genes tested, both IPNV-VP2NP and 
VHSV-G-frg16NP evoked upregulation, significantly different 
from the untreated control (Figure 4) as follows: vig1 5.6 ± 4.1 
and 5.1 ± 3.2-fold for IPNV-VP2NP and VHSV-G-frg16NP, respec-
tively; continuing in that order ifit5 7.1 ± 1.7 and 6.9 ± 1.6; ccl4 
16.9 ± 10.8 and 16.2 ± 10.2; mx 2.6 ± 1.4 and 3.3 ± 1.1; mda5 
3.0 ± 1.8 and 3.3 ± 1.2. For all genes tested, the poly(I:C) positive 
control elicited higher upregulation than the NPs, but the differ-
ence was not as great as seen in ZFL. Note in this case, the poly(I:C) 
dose used was the same (10 µg/ml) as for the NPs whereas in ZFL 
we used 25  µg/ml (29). The most similar response to stimulus 
with the NPs was seen in mda5 which was upregulated 7.1 ± 1.3 
with poly(I:C) treatment. iRFPNP treatment only significantly 
upregulated 1 gene very weakly, ifit5 1.8 ± 0.4-fold.
Uptake of nPs by Zebrafish via intubation
In preliminary in vivo experiments, adult zebrafish (n = 3) were 
intubated with the viral NPs at 20 and 50 μg/fish and sampled 
at 6, 24, and 48  h. By 24  h, the percentage of fluorescent cells 
had dropped by approximately 50% compared with 6  h and 
had dropped further by 48 h, indicating early uptake of the NPs 
in vivo (data not shown). Hence, the intubation experiments with 
larger numbers of fish, reported here (Figure 5), were done at a 
short time interval of 5 h. Adult zebrafish were able to take up 
the three viral NPs into gut cells when administered orally via 
intubation at 20 μg/fish. For IPNV-VP2NP, 75% of the fish intu-
bated had taken up the NP after 5 h, while for VHSV-G-frg16NP 
and VNNV-CNP, 100% of the fish intubated internalized the NPs 
(n =  8). The range and mean of the percentage of fluorescent 
cells (10,000 events) (Figure 5 upper graph) were: range 0–23%, 
mean 13% for IPNV-VP2NP, range 8–19%, mean 13% for VHSV-
G-frg16NP, and range 10–47%, mean 20% for VNNV-CNP. The 
MFI results (Figure 5 lower graph) in general clustered around 
the average for each group, being 186, 151, and 191 for IPNV-
VP2NP, VHSV-G-frg16NP, and VNNV-CNP, respectively. Note the 
fluorescence labeling efficiency with Atto-488 NHS was lower for 
VHSV-G-frg16NP compared with the other two NPs (see Figure 
S1 in Supplementary Material). This explains the lower average 
MFI in intestine cells which had taken up VHSV-G-frg16NP.
DiscUssiOn
The thrust of our work is to seek a safe and effective, but emi-
nently practical solution for fish vaccination in the long term. To 
this purpose, we have successfully produced three viral antigenic 
proteins in E. coli as IBs. The production of these “nanopellets” 
followed a simple, fully scalable, batch culture procedure in 
FigUre 4 | Gene expression analysis in RT-HKM stimulated with salmonid viral nanopellets (NPs). Cells were incubated for 15 h as follows: unstimulated control 
cells (black), poly(I:C) 10 µg/ml as a positive control (blue), IPNV-VP2NP 10 µg/ml (white), VHSV-G-frg16NP 10 µg/ml (gray), and iRFPNP 10 µg/ml as an 
immunogenically irrelevant NP control (red). Samples are from two independent experiments. Data are mean ± SD (n = 4). Gene expression was determined by 
quantitative real-time PCR with three technical replicates. Differences between each treatment mean and control were analyzed by unpaired one-sided t-tests with 
Welch’s correction for unequal variances. Significance levels *p < 0.05; **p < 0.01; ***p < 0.001.
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E. coli, with isolation by mechanical and enzymatic methods. 
This is a more straightforward, less costly approach than that 
required to produce VLPs (8), or purified soluble recombinant 
proteins and avoids safety issues raised regarding DNA vaccines. 
Concerning biocompatibility, the NPs were not toxic to ZFL cells 
nor were there any signs of malaise in adult zebrafish intubated 
with up to 50 µg/fish for 48 h. In previous work, we have injected 
IBs at up to 300  µg/zebrafish and maintained the animals for 
30 days with no signs of any deleterious effects (13). We therefore 
consider the recombinant protein NPs are innocuous to fish. 
Having successfully produced the NPs, we wished to address 
two critical questions at this stage: Could the NPs be taken up 
in fish? And, would an initial immune response be evoked, given 
the importance of the innate immune response in establishing an 
effective adaptive immune response to vaccination (30)?
As regards uptake, an advantage of IBs is that the amyloid 
scaffold can protect the functional protein from degradation 
while passing through the low pH of the gastrointestinal tract. 
We have already successfully tested other NPs resistance at pH 2.5 
and uptake in intubated trout (13). The scaffold itself is resistant 
to proteinase K digestion but represents approximately 20% of 
the protein in the structure (31), leaving a considerable amount 
of functional protein to be released slowly within the organism. 
Here, we tested first, uptake in vitro in ZFL and then in vivo in 
zebrafish via intubation. In ZFL all three NPs were taken up 
O/N, achieving ≥  50% of the cells sampled. VHSV-G-frg16NP 
uptake was strikingly efficient even at 6 h, the earliest time point 
tested. The abundant uptake of VHSV-G-frg16NP by ZFL was cor-
roborated by the confocal microscopy results. For the two other 
NPs, uptake was also high in susceptible cells, but not all cells 
had internalized the particles. The VHSV-G-frg16NP construct 
contains an arginine-glycine-aspartic acid (RGD) tripeptide 
integrin binding site (18, 19), not present in IPNV-VP2NP nor 
VNNV-CNP. RGD-binding integrins are known receptors or 
coreceptors for certain viruses (32). In addition, in experiments 
on IB uptake in HeLa cells, an IB with the RGD site mutated to 
RGE was internalized significantly less than that with RGD (24). 
We thus hypothesized the RGD site in VHSV-G-frg16NP may be 
facilitating IB uptake in ZFL.
The in vivo uptake results in zebrafish were also encouraging. 
The three NPs were able to be taken up by almost all fish tested via 
the intestine in a matter of hours. The zebrafish gut is composed 
of intestinal epithelial cells, goblet cells, smooth muscle cells 
[see Figure 1A in Ref. (33)], and immune cells also known as 
gut-associated lymphoid tissue (GALT). The fish GALT is less 
structured than the mammalian GALT. It contains two main 
populations of immune cells: the leukocytes in the lamina pro-
pria, which include various immune cells, such as granulocytes, 
macrophages, lymphocytes, and plasma cells; and intraepithelial 
lymphocytes, composed of T cells and some B cells located among 
epithelial cells. These immune cells together regulate gut immune 
responses. The GALT is particularly important because it is the 
main immune tissue involved in the uptake and processing of 
orally administrated antigens (10). We found an average of 13, 
13, and 20% of cells had taken up IPNV-VP2NP, VHSV-G-frg16NP, 
and VNNV-CNP, respectively, 5 h after oral administration of a 
single dose. We do not know which specific cell type is taking up 
the viral NPs but in previous work we have shown that cytokine-
made NPs can be found in the lamina propria (midgut) and in the 
villi apex where lymphoid cells are located (13).
The development of the zebrafish intubation method used 
should also be noted. We are able to successfully administer up 
FigUre 5 | Uptake of nanopellets (NPs) by zebrafish via intubation. Adult 
zebrafish were intubated with 20 μg/fish of each fluorescently labeled NP in 
30 µl PBS for 5 h (n = 8), then intestine cells were sampled for cytometry. ● 
Control fish: 30 µl PBS intubated without NP. Each point represents data 
from one fish intubated with ■ IPNV-VP2NP, ▾ VHSV-G-frg16NP, or ♦ 
VNNV-CNP. Horizontal bars are the means. Differences between the mean of 
each treatment group and control were analyzed by an unpaired one-sided 
t-test with Welch’s correction for unequal variances. Significance levels 
*p < 0.05; **p < 0.01; ***p < 0.001.
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strategy to evoke mucosal immune stimulus. Nevertheless, while 
antigen uptake is a point in favor, it is by no means a guarantee of 
an immune response, as the gut environment is highly tolerogenic. 
This is one of the main challenges in oral vaccine development, 
which we will need to face further down the pipeline (10, 34).
At this stage, the other issue studied here regarding the 
potential use of NPs was whether they could evoke an antiviral 
innate immune response. We therefore stimulated ZFL cells 
with the three viral antigen NPs and the control iRFPNP and 
checked expression of innate immune gene markers of viral 
infection: IFN-stimulated genes (35) including transcription 
factors irf7 and stat1b and genes encoding antiviral peptides mx 
and viperin (vig1) (36), as well as gig2 and chemokine ccl4. The 
viral dsRNA mimic, poly(I:C), was used as a positive control as 
it mounts an antiviral response in zebrafish (29) among other 
species, and as such is being tested as a potential fish vaccine 
adjuvant (37). The results for VNNV-CNP were particularly 
promising. All six genes tested were highly upregulated, attain-
ing similar levels to those obtained with poly(I:C). IPNV-VP2NP 
also caused significant but much lower up regulation, while 
VHSV-G-frg16NP only upregulated three of the genes at lower 
levels. Upregulation by the control NP, iRFPNP was slight or 
negligible. The poly(I:C) positive control was not conceived 
for direct quantitative comparison, as it mimics nucleic 
acid, not protein. For this reason, we were surprised that the 
upregulation of the innate immune genes tested appeared so 
similar, between VNNV-CNP and poly(I:C). Multiple activation 
pathways are triggered by viral infection (38), but we had not 
expected such a comparable profile of gene upregulation by the 
recombinant protein and the viral dsRNA mimic. Apparently, 
we had achieved an innate antiviral response in full swing, by 
two quite different stimuli.
Indeed, the role of viral capsid proteins in innate immune 
stimulus is starting to be elucidated by research in mammalian 
systems. It appears that innate immune activation can be medi-
ated by recognizing the intrinsic order of capsid structure. For 
instance, TRIM5 has been reported as a pattern recognition 
receptor, specific for retrovirus capsid lattice (39). Furthermore, 
toll-like receptor 2 has recently been shown to respond to the 
multi-subunit arrangement of viral capsids, independent of amino 
acid sequence, or specific morphology. Rather, stimulus relies on 
repeating protein subunits, as a conserved common denominator 
across viral capsids (40). We do not know how well our NPs fit 
into this descriptor, but IBs are entities composed of repeated 
subunits in an ordered nanostructure. Fourier transform infrared 
microspectroscopy shows that IBs are proteins with native-like 
structure entrapped in densely packed intermolecular β-sheet 
bridges (41). The relative amount of native-like protein can differ 
with production conditions. Out of interest, we checked crystal-
lography data from a VLP of Grouper nervous necrosis virus (42), 
another marine betanodavirus. The self-assembled particle size 
is typical of the Nodaviridae 30–35 nm, and the shell domain has 
the common viral capsid protein jelly roll structure with eight 
β strands forming two antiparallel sheets (43). Our VNNV-CNP 
is considerably larger (~420 nm) than the VLP and we do not 
know the 3D structure further than the order inferred from the 
FESEM images. We also do not know if there is self-assembly 
to 30 µl, to fish of mean weight 0.9 ± 0.2 g simply and quickly, 
without injuring the animals. The fact that fish were able to take 
up the NPs via the oral route is crucial as a proof of concept for a 
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of the native-like viral capsid protein as it emerges from the IB 
scaffold. Nevertheless, our results imply that this NP triggered an 
innate immune response in ZFL cells as if it were a virus.
It should also be pointed out that the NPs, while made mainly 
of viral protein subunits, contain low amounts of bacterial nucleic 
acids, peptidoglycan, and lipopolysaccharide (14). The non-
relevant immune control, iRFPNP also has these contaminants but 
was a poor stimulator of the antiviral response both in ZFL and 
HKM cells. This does not preclude stimulus of other genes. In 
fact, in prior work, when iRFPNP was injected in zebrafish and a 
challenge with P. aeruginosa was performed, there was significant 
survival of treated fish compared with control. The protection was 
presumably due to stimulus evoked by these contaminants (14).
Regarding IPNV-VP2NP and VHSV-G-frg16NP, the important 
consideration for our purposes was that the NPs could stimulate 
the chosen viral response gene markers, more than the size of 
the effect. In this vein, we were concerned that VHSV-G-frg16NP 
had not produced stimulus in several of the genes tested in ZFL. 
It should be kept in mind that this NP construct is not the whole 
antigenic protein, in contrast to the other NPs, but it has antigenic 
epitopes including Mx inducing sites (18). Given that tropism 
might be a significant factor, we tested the expression of viral 
response gene markers, induced by IPNV-VP2NP and VHSV-G-
frg16NP in RT-HKM primary cultures, as trout is a natural host for 
IPNV and VHSV. In these experiments, we included ifit5 (27) and 
mda5 (35) an IFN-induced gene and a dsRNA receptor belonging 
to the RIG-1-like receptor family, respectively. In this case, we got 
significant stimulus of all the gene markers, at a similar level for 
both NPs.
Summarizing, we have produced three recombinant viral 
antigenic proteins as nanostructured biomaterials with view to 
use in orally delivered prophylaxis. The methodology employed is 
straightforward, cheap, and fully scalable. These “nanopellets” are 
successfully taken up in vitro in ZFL and in vivo in zebrafish via 
oral administration. They stimulate an antiviral innate immune 
response both in ZFL and RT-HKM cells. They therefore are 
candidates for immunostimulants. On the road to vaccine devel-
opment, the next essential steps are to run protection studies and 
to demonstrate the raising of antigen-specific antibodies in target 
fish species. We are keen to further explore their potential.
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